For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for UnitedHealth Group Incorporated (UNH) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -47 (−100…+100 Quality+Value blend) · Quality -31 · Value -60 · Sentiment 21 (timing only, not weighted) · Composite fair value $364.92 vs $421.47 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
UnitedHealth Group Incorporated
UNH NYSEUnitedHealth Group Incorporated is an American multinational health care company headquartered in Eden Prairie, Minnesota, founded in 1974. It operates through two primary brands: UnitedHealthcare, which provides health insurance and managed care services, and Optum, which delivers health care services, technology, and data analytics. UnitedHealthcare offers benefit plans for employers, individuals, Medicare and retirement members, community and state programs including Medicaid, and global markets in South America. Optum encompasses OptumHealth for care delivery, wellness, and health financial services; OptumInsight for data analytics and consultancy; and OptumRx for pharmacy benefit management. The company serves patients, providers, payers, employers, and public-sector entities across the United States and internationally, focusing on care management, consumer engagement, and improving health system efficiency. UnitedHealth Group Incorporated plays a central role in the health care sector by integrating insurance with innovative services and technology solutions.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 13.23
Total Equity: $101.70B
Shares: 911,000,000
Total Debt: $78.39B
Cash: $24.37B
EBITDA: $23.33B
Total Debt: $78.39B
Cash: $24.37B
Revenue: $447.57B
Revenue: $447.57B
Revenue: $447.57B
Total Equity: $101.70B
Tax Rate: 12.9%
Equity: $101.70B
Total Debt: $78.39B
Cash: $24.37B
Current Liabilities: $114.90B
Long-Term Debt: $72.32B
Total Debt: $78.39B
Total Equity: $101.70B
Shares: 911,000,000
Shares: 911,000,000
CapEx: -$3.62B
Shares: 911,000,000
Stock Price: $421.47
Net Income: $12.06B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 31, 2026 12:31am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $287.6B | $324.2B | $371.6B | $400.3B | $447.6B |
| Cost of Revenue | $31.0B | $33.7B | $38.8B | $46.7B | $50.7B |
| Gross Profit | $256.6B | $290.5B | $332.9B | $353.6B | $396.9B |
| Operating Expenses | $232.6B | $262.0B | $300.5B | $321.3B | $377.9B |
| Operating Income | $24.0B | $28.4B | $32.4B | $32.3B | $19.0B |
| Net Income | $17.3B | $20.1B | $22.4B | $14.4B | $12.1B |
| EBITDA | $27.1B | $31.8B | $36.3B | $36.4B | $23.3B |
| EPS | $18.33 | $21.47 | $24.12 | $15.64 | $13.28 |
| EPS (Diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 12:02am (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $21.4B | $23.4B | $25.4B | $25.3B | $24.4B |
| Total Current Assets | $61.8B | $69.1B | $78.4B | $85.8B | $90.6B |
| Total Assets | $212.2B | $245.7B | $273.7B | $298.3B | $309.6B |
| Current Liabilities | $78.3B | $89.2B | $99.1B | $103.8B | $114.9B |
| Long-Term Debt | $42.4B | $54.5B | $58.3B | $72.4B | $72.3B |
| Total Liabilities | $135.7B | $159.4B | $174.8B | $195.7B | $207.9B |
| Total Equity | $76.5B | $86.3B | $98.9B | $102.6B | $101.7B |
| Retained Earnings | $77.1B | $86.2B | $95.8B | $96.0B | $95.6B |
Cash Flow (Annual)
Last updated: Jul 31, 2026 12:31am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $22.3B | $26.2B | $29.1B | $24.2B | $19.7B |
| Capital Expenditure | -$2.5B | -$2.8B | -$3.4B | -$3.5B | -$3.6B |
| Free Cash Flow | $19.9B | $23.4B | $25.7B | $20.7B | $16.1B |
| Acquisitions (net) | -$4.8B | -$21.5B | -$10.1B | -$13.4B | -$4.5B |
| Net Debt Issued / (Repaid) | $3.8B | $11.8B | $4.3B | $14.8B | -$81.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$5.0B | -$7.0B | -$8.0B | -$9.0B | -$5.5B |
| Net Change in Cash | $4.5B | $2.0B | $2.1B | -$115.0M | -$947.0M |
Growth Trends (YoY %)
Last updated: Jul 31, 2026 12:31am (23d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +12.7% | +14.6% | +7.7% | +11.8% |
| Gross Profit Growth | +13.2% | +14.6% | +6.2% | +12.3% |
| Operating Income Growth | +18.6% | +13.8% | -0.2% | -41.3% |
| Net Income Growth | +16.4% | +11.2% | -35.6% | -16.3% |
| EBITDA Growth | +17.6% | +14.1% | +0.2% | -35.9% |
Dividend History (Last 20)
Last updated: Jul 31, 2026 12:02am (23d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-15 | $2.32 | — | — | — |
| 2026-03-09 | $2.21 | — | — | — |
| 2025-12-08 | $2.21 | — | — | — |
| 2025-09-15 | $2.21 | — | — | — |
| 2025-06-16 | $2.21 | — | — | — |
| 2025-03-10 | $2.10 | — | — | — |
| 2024-12-09 | $2.10 | — | — | — |
| 2024-09-16 | $2.10 | — | — | — |
| 2024-06-17 | $2.10 | — | — | — |
| 2024-03-08 | $1.88 | — | — | — |
| 2023-12-01 | $1.88 | — | — | — |
| 2023-09-08 | $1.88 | — | — | — |
| 2023-06-15 | $1.88 | — | — | — |
| 2023-03-10 | $1.65 | — | — | — |
| 2022-12-02 | $1.65 | — | — | — |
| 2022-09-09 | $1.65 | — | — | — |
| 2022-06-16 | $1.65 | — | — | — |
| 2022-03-11 | $1.45 | — | — | — |
| 2021-12-03 | $1.45 | — | — | — |
| 2021-09-10 | $1.45 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 11:13Recovery pays +53%; another quarter like the worst recent one costs 64%. Ratio 0.8:1.
| Case | Growth | Margin | Fair value | vs price ($421.47) |
|---|---|---|---|---|
| Bull — recovery | +7% | 9.2% | $646.11 | +53% |
| Base — stabilizes | +5% | 8.0% | $522.81 | +24% |
| Bear — keeps slipping | +2% | 6.8% | $413.95 | -2% |
| Stress — last quarter repeats | +12% | 1.6% | $150.57 | -64% |
Narrative Economics
market-narrative step).
Claude Reading
The raw numbers tell a story that most of the prior models are underweighting: UNH's earnings collapse is real and accelerating, not a one-time regulatory blip. Look at the quarterly NI trajectory: $6.06B → $5.54B → $6.29B → $3.41B → $2.35B → $10M(!) → $6.28B. That Q4 2025 print of essentially zero net income on $113B of revenue is not noise — it reflects reserve strengthening, Medicare Advantage V28 recoding pain, and MLR blowout. FY2025 net income of $12.06B is down 46% from $22.38B in 2023, on revenue that grew 20% over the same span. Operating margin collapsed from 8.7% (2023) to 4.2% (2025). This is not a mature earner in steady state — it's a mature earner with a broken profit engine, and the archetype classification of "mature_earner" with 0.73 confidence is misleading because it obscures the trajectory.
The synthesis verdict of "fully_priced" at $337.60 signal-adjusted vs $421 spot is directionally right but arguably too generous. A 31.8x P/E on TTM earnings that just cratered assumes a snapback to $20B+ NI. If 2026 earnings recover to a midpoint of, say, $16B (below 2023's peak, above 2025's trough), you're paying 24x on recovery earnings — still not cheap for a company facing MA reimbursement headwinds through 2026, PBM regulatory scrutiny, and a DOJ investigation into MA billing practices. The Market Forces module's "catastrophic profit collapse" framing is hyperbolic but closer to the data than the Thesis Evaluation's "utility-like" reading — you cannot simultaneously claim utility-like stability and observe a 46% earnings decline in two years. Those two prior models directly contradict each other and the Thesis Evaluation is simply wrong on the facts.
The contrarian bull case worth taking seriously: UNH has historically over-reserved during transition years, and MA rate notices for 2026 (+5.06% final) came in materially better than 2025. Optum Health membership under value-based care continues to grow, and OptumRx remains a cash machine. FCF of $16.08B on a $383B market cap is a 4.2% FCF yield — not screaming cheap but not egregious for a franchise with 10%+ revenue CAGR. If you believe 2025 was the kitchen-sink year (Brian Thompson assassination fallout, Change Healthcare cyberattack tail costs, MA recoding), then 2027 EPS could re-approach $30 and the stock is a coiled spring. The dividend yield of 2.1% with a fortress balance sheet ($24B cash, $78B debt against $101B equity) gives you paid-to-wait optionality. That said, the current_ratio of 0.79 and ROA of 3.9% are unimpressive, and I distrust the narrative-layer's "platform-monopoly" framing — UNH is a regulated insurer with a services arm, not Visa.
I partially agree with the synthesis but land more bearish on conviction. Fair value in the $340–$370 range feels right for a business earning ~$14–16B normalized, applying a 22–24x multiple that reflects both franchise quality and structural earnings uncertainty. At $421, you're paying for a recovery that hasn't been confirmed by two consecutive clean quarters — Q1 2026's $6.28B NI is encouraging but one data point. Insider activity isn't in the file, which is a gap: I'd want to see whether Witty and the CFO are buying at these levels given how loud their "trough is behind us" messaging has been. The prior models collectively converge on "overvalued by ~20%" and I concur with that magnitude, but I'd weight the downside risk higher than the composite does because the earnings base is still unstable and regulatory overhang (PBM legislation, MA audits, potential vertical breakup pressure) is asymmetric to the downside. This isn't a zero — it's a great franchise being repriced — but the risk/reward at $421 favors patience over accumulation. I'd want $350 or a clean two-quarter earnings pattern before committing capital.
GPT Reading
The raw numbers say UNH is no longer a clean “compounder at a premium” story; it is a revenue machine with damaged earnings power. Revenue has kept climbing from $287.6B in 2021 to $447.6B in 2025, a 9.7% CAGR, and the quarterly run-rate is still above $111B, with 2026 Q1 up to $111.72B from $109.58B a year earlier. But underneath that scale, profitability has clearly broken. Operating income was basically flat at about $32.3B in both 2023 and 2024, then fell hard to $19.0B in 2025 despite nearly $47B of added revenue. Net income went from $22.38B in 2023 to $14.41B in 2024 to $12.06B in 2025. That is not a temporary wobble you wave away when the stock still trades at 31.9x earnings and 18.7x EV/EBITDA. The quarterly pattern reinforces it: margins were 5.5%-6.0% through late 2024, then 5.7% in 2025 Q1, then slid to 3.1%, 2.1%, and effectively 0% in 2025 Q4 before recovering to 5.6% in 2026 Q1. That rebound matters, but one quarter does not erase a year in which scale translated into almost no incremental profit.
What stands out most is the mismatch between valuation and economic quality at the current point in the cycle. On 2025 numbers, UNH generated $16.08B of free cash flow against a $382.8B market cap, a roughly 4.2% FCF yield, and only $12.06B of net income, a roughly 3.1% earnings yield. For a business with a current ratio below 0.8, net debt around $54B, and visibly unstable margins, that is expensive. P/S at 0.86x looks optically modest only because this is a gigantic low-margin business; what matters is that net margin compressed to 2.7% in 2025 from 5.6% in 2023. If the business were still earning even close to its 2023 margin structure, today’s price could be defended. On actual reported results, it looks like the market is capitalizing peak-franchise confidence rather than current earnings power. I do not buy the idea that this should carry a huge premium simply because it is “integrated.” Vertical integration is only worth a premium if it stabilizes costs and expands margins; the data here show the opposite over the last two years.
The encouraging counterpoint is that this may already include a severe but transient earnings reset rather than a permanent impairment. Revenue growth has not cracked, free cash flow remains solid at $19.7B operating cash flow and $16.1B FCF, ROE is still 11.9%, and 2026 Q1 net income of $6.28B nearly matched 2025 Q1’s $6.29B despite the ugly intervening quarters. If that 2025 Q4 collapse to just $10M of net income reflected discrete charges, reserve actions, or one-off repricing pain rather than a new baseline, then the annual 2025 P/E is overstating ongoing valuation badly. A bull would also argue that on a normalized earnings base closer to $20B, the stock would be closer to 19x earnings, which is not absurd for the sector leader with Optum-like diversification. That is the best argument against my skepticism, and it is a real one: the latest quarter suggests franchise demand and pricing power are intact enough to recover.
I still weigh the risk side more heavily because the burden of proof is now on margins, not on revenue. A business that adds $76B of revenue from 2023 to 2025 but loses $13.4B of net income is telling you that cost control, reimbursement, or mix has turned hostile. Even if 2026 normalizes, investors at $421 are paying as though normalization is probable and durable. I would want a larger margin of safety for a company whose annual operating margin fell from 8.7% in 2023 to 4.2% in 2025. What changes my mind is straightforward: if the next two to three quarters show net margins holding near or above 5.5% on the current $112B+ quarterly revenue base, that implies an annualized earnings run-rate above $24B and makes today’s price look much more reasonable. Alternatively, if 2026 operating cash flow re-accelerates well above $22B with no resurgence of reserve or cost issues, I would concede the 2025 collapse was aberrational. If instead margins slip back toward the 2%-3% range, fair value is much lower than today’s quote and the stock deserves to de-rate toward a more traditional managed-care multiple.
Grok Reading
The raw numbers tell a story of a franchise that is growing the top line while watching its earnings power erode at an alarming rate. UnitedHealth put up $447.57B in 2025 revenue, an 11.8% year-over-year advance and a clean 9.7% multi-year CAGR, yet operating income collapsed from $32.29B in 2024 to $18.96B and net income fell to $12.06B—half the $22.38B earned two years earlier. The fourth quarter of 2025 was an outright wipeout: $113.22B of revenue produced just $10 million of net income. Margins that once sat comfortably in the mid-to-high single digits now print 2.7% at the net line and 4.2% at the operating line. Free cash flow of $16.08B still covers the dividend and leaves a residual, but the FCF CAGR of –20.9% confirms that cash generation is tracking the earnings decline, not offsetting it. At $421.47 the stock trades at 31.9× those depressed trailing earnings and 18.7× EV/EBITDA—multiples that embed a recovery narrative the income statement has so far refused to validate.
The Optum platform story is the only coherent explanation for why a company with a 2.7% net margin and negative earnings momentum still commands a software-like earnings multiple rather than the 15–18× typical of mature managed-care names. Vertical integration was supposed to produce durable mix shift toward higher-margin care delivery, pharmacy, and data services; instead 2025 delivered the opposite—Medicare Advantage rate pressure and elevated medical-cost trends overwhelmed any Optum contribution and drove a structural step-down in profitability. Balance-sheet metrics remain serviceable (debt-to-equity 0.77, $24.4B cash against $78.4B debt), so solvency is not the issue; the issue is that the market is paying a 25% narrative premium (current price versus the $337 signal-adjusted fair value) for synergies that have not appeared in reported margins or ROIC of only 10.6%.
The strongest counter-argument is that 2025 was an aberrational trough driven by one-time Medicare Advantage repricing and medical-cost spikes, and that the Q1 2026 rebound to $6.28B net income (5.6% margin) already signals normalization. If the company can re-establish the $20B-plus net income run-rate of 2022–2023, the forward multiple compresses into the high teens and the stock looks merely fully valued rather than expensive. Bulls will also note that revenue visibility remains high, FCF conversion is still solid, and the 2.1% dividend yield provides a floor while the platform thesis plays out. I weigh this less heavily because the margin compression has now persisted across four consecutive quarters of 2025, the earnings CAGR is –26.6%, and regulatory scrutiny of PBMs and vertical integration is intensifying rather than fading—hardly the setup for a clean V-shaped profit recovery.
I would reverse to a neutral or constructive stance if two consecutive quarters deliver operating margins back above 7% and full-year 2026 guidance implies net income of at least $18–20B, or if management demonstrates Optum segment margins expanding enough to offset UnitedHealthcare medical-cost pressure in a transparent segment bridge. Absent that evidence, the stock is priced for a turnaround that the fundamentals have not yet earned.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
UnitedHealth remains a scale mature earner: revenue compounded from $287.6B in 2021 to $447.6B in 2025 (roughly 12% CAGR), FCF ran $16-26B annually, and the diluted share count fell from 956M to 911M (about -1.2% CAGR) with buybacks running 7x SBC. Earnings-quality mechanicals are clean: accruals -2.6% of assets, OCF/NI 1.44x, Beneish M -2.58, Altman Z 3.09 (safe zone). Liquidity is adequate ($28.1B cash, $16B FCF) even with net debt of -$50.3B. The concern is a real and recent deterioration in profitability. Operating margin collapsed from 8.7% in 2023 to 8.1% in 2024 to just 4.2% in 2025, and net income fell two years running from $22.4B (2023) to $14.4B (2024) to $12.1B (2025) despite revenue still growing 12%. FCF also stepped down from $25.7B to $16.1B. That is a structural earnings problem - likely medical-loss-ratio pressure in Medicare Advantage and/or Optum issues - not an accounting one, which is why the earnings-quality screens still pass. Net: the balance sheet, cash conversion, and capital-return discipline still describe a healthy franchise, but the underwriting/operating economics have taken a genuine hit that has not yet stabilized. This is a strong business under real operational strain, not a broken one, and not (yet) a fortress-grade compounder either.
Verify before trusting this (7)
- Medicare Advantage medical loss ratio trend and 2025 bid positioning
- Whether the 2025 margin hit includes one-time items (cyberattack costs, DOJ matters, reserve strengthening) vs run-rate MLR pressure
- Optum Health segment margin trajectory and V28 risk-adjustment impact
- Any change in reserve methodology or IBNR assumptions in the 10-K
- Debt maturity ladder and interest coverage given the -$50B net debt position
- Insider selling/buying pattern during the 2024-2025 earnings decline
- Regulatory and DOJ exposure disclosures
The stack lines up close to the tape: composite FV $414 sits 2% below the $421.47 price, and the signal-adjusted FV of $338 implies roughly 20% downside once you haircut for the ongoing margin collapse. The DCF at $562 is the outlier and I discount it heavily - it is extrapolating pre-deterioration cash flows through a period when operating margin has fallen 460bp and net income has declined two years running. The EPV floor at $330 and anchored PE at $201 are the more sobering anchors and both sit well below spot. Triangulating, deserved value is somewhere in the $340-$415 band, with $380 a reasonable midpoint. Price at $421 is inside or slightly above that band. This is a solid business the market already understands - platform-monopoly narrative is priced in, and the earnings-quality is high enough that I do not further haircut, but I also cannot manufacture upside from a stock trading at fair value on a business whose operating engine is misfiring. Margin of safety is essentially zero. To get interested I need the price to give me a real cushion against the risk that MLR pressure and Optum integration issues persist another year.
Verify before trusting this (4)
- MLR trajectory next 2 quarters - is medical cost ratio stabilizing or still climbing
- Optum Health operating margin recovery and any one-time integration/impairment charges
- Guidance revisions vs consensus for 2025 EPS - is the margin bottom in
- DOJ/FTC posture on vertical integration and any PBM legislation risk quantified in filings
The tape is neutral-with-a-tilt: VIX at 17, S&P off 2.3% from highs, 10y at 4.67% and a market PE of 26 - a mildly hostile macro backdrop, but UNH's 0.63 beta means the market pressure barely lands here. This is a defensive, low-beta managed-care name in a tape that isn't hunting risk, so macro is a non-event either way. The narrative is the real story. The platform-monopoly frame is moderate/moderate with low cult - not a mania, not a collapse - and recent news flow has clearly turned constructive: analyst fair-value marks stepped from ~$424 to ~$475 (+12%) on Q2, a value-manager letter is publicly reframing UNH from 'overlooked to recognized,' and peer Cigna's strong print without the surprise-billing hit reinforces that managed-care fundamentals are intact. That is a genuine, if measured, tailwind. Cutting the other way: the same Cigna note flags UNH-specific inflated dispute-resolution costs, vertical-integration and PBM political scrutiny remain a live sector overhang, and the stock is already ~25% above DCF - the narrative has to keep delivering. Net: a fading-headwind, rebuilding-tailwind setup that roughly balances out, with the edge slightly to the upside as the 'recovering' narrative regains traction.
Verify before trusting this (4)
- Whether the string of target hikes broadens beyond Q2 reactions into full-year 2026 revisions
- Any DOJ/FTC news on Optum or PBM structure - a fresh probe would re-open the headwind
- Follow-through on the 'recovering from overlooked' narrative in more manager letters and sell-side notes
- Sector rotation signals - if defensives lead a risk-off leg, low-beta UNH gets a relative bid
This lens hasn't been run for this ticker yet.
When we made this prediction on Jul 31, 2026, UNH was $421.47. We expect it to be $410.00 by Jan 2027, and we consider it great value under $340.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Jul 31, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.